Zeke Capital Advisors LLC raised its stake in shares of Colgate-Palmolive (NYSE:CL) by 137.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,847 shares of the company’s stock after purchasing an additional 9,745 shares during the period. Zeke Capital Advisors LLC’s holdings in Colgate-Palmolive were worth $1,227,000 at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Colgate-Palmolive by 2.4% in the second quarter. Vanguard Group Inc. now owns 67,875,384 shares of the company’s stock worth $5,031,602,000 after acquiring an additional 1,621,392 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Colgate-Palmolive by 42.4% in the second quarter. Renaissance Technologies LLC now owns 9,753,400 shares of the company’s stock worth $723,020,000 after acquiring an additional 2,903,800 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Colgate-Palmolive by 25.3% in the second quarter. Arrowstreet Capital Limited Partnership now owns 6,854,323 shares of the company’s stock worth $508,111,000 after acquiring an additional 1,385,946 shares in the last quarter. First Eagle Investment Management LLC increased its position in shares of Colgate-Palmolive by 35.8% in the third quarter. First Eagle Investment Management LLC now owns 6,641,548 shares of the company’s stock worth $483,837,000 after acquiring an additional 1,750,417 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its position in shares of Colgate-Palmolive by 3.7% in the second quarter. TIAA CREF Investment Management LLC now owns 4,725,042 shares of the company’s stock worth $350,267,000 after acquiring an additional 170,053 shares in the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.
In other Colgate-Palmolive news, Director Stephen I. Sadove sold 20,780 shares of the stock in a transaction on Monday, November 6th. The shares were sold at an average price of $70.52, for a total transaction of $1,465,405.60. Following the transaction, the director now directly owns 36,268 shares in the company, valued at approximately $2,557,619.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jennifer Daniels sold 902 shares of the stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $75.82, for a total transaction of $68,389.64. Following the transaction, the insider now owns 37,788 shares in the company, valued at $2,865,086.16. The disclosure for this sale can be found here. Insiders sold 181,950 shares of company stock valued at $13,237,385 over the last 90 days. Insiders own 1.02% of the company’s stock.
Colgate-Palmolive (NYSE:CL) last announced its earnings results on Friday, October 27th. The company reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. The business had revenue of $3.97 billion during the quarter, compared to the consensus estimate of $3.94 billion. Colgate-Palmolive had a net margin of 15.10% and a return on equity of 2,782.56%. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.73 earnings per share. analysts anticipate that Colgate-Palmolive will post 2.88 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Tuesday, January 23rd will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.15%. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 61.78%.
Several equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Colgate-Palmolive from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Jefferies Group reissued a “hold” rating and issued a $79.00 price objective on shares of Colgate-Palmolive in a research report on Thursday, September 28th. Macquarie assumed coverage on shares of Colgate-Palmolive in a research report on Thursday, September 14th. They issued a “neutral” rating and a $76.00 price objective for the company. Royal Bank of Canada reissued a “hold” rating and issued a $74.00 price objective on shares of Colgate-Palmolive in a research report on Sunday, October 8th. Finally, Citigroup dropped their price objective on shares of Colgate-Palmolive from $76.00 to $75.00 and set a “neutral” rating for the company in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $76.51.
TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2018/01/12/colgate-palmolive-cl-shares-bought-by-zeke-capital-advisors-llc.html.
Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.